EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Clinical outcomes and adjuvant therapy in stage IC endometrial cancer under the revised 2023 FIGO staging system: a multicenter analysis

Xiaolin Meng iD, Jing Yuan iD, Qian Zhang iD, Shuaiqingying Guo iD, Chaoyang Sun iD, Qing Zhang iD, Yingmei Wang iD, Kezhen Li iD, Jihui Ai iD, Jie Yang iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e57 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Xiaolin Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Technology Research and Development Program of China, National Clinical Research Centre of Obstetrics and Gynaecology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The revised 2023 International Federation of Gynecology and Obstetrics (FIGO) staging scheme for endometrial cancers (ECs) classifies tumors without myometrial invasion and with a non-aggressive histology as stage IA1, while those with aggressive histology are upgraded to stage IC. However, clinical guidelines lack evidence regarding prognostic and treatment strategies. This study evaluated survival outcomes of stage IC ECs and the impact of adjuvant therapy. METHODS: Data from the Chinese cohort and the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively analyzed. Overall survival (OS) and recurrence-free survival (RFS) were assessed using Kaplan-Meier curves and Cox-regression methods to assess treatment outcomes and identify risk factors. RESULTS: Patients with stage IC had poorer 5-year-RFS (China: IA1 vs. IC, 97.5% vs 92.84%) and OS (SEER: IA1 vs. IC, 95.95% vs. 86.25%) than stage IA1. Despite 34/44 (77.3%) patients from China and 483/886 (54.5%) patients from SEER cohort received adjuvant therapy, no RFS (Chinese cohort, p=0.489) or OS (SEER cohort, p=0.560) improvement was observed, and neither chemotherapy, radiotherapy, nor their combination improved prognosis than no adjuvant therapy for ECs in stage IC ECs. Non-endometrioid histology was the only independent risk factor for worse OS (hazard ratio=1.672, 95% confidence interval=1.009-2.77). Subgroup analyses revealed no survival benefit from adjuvant treatment in endometrioid (p=0.943) or non-endometrioid (p=0.884) tumors. CONCLUSION: In ECs without myometrial invasion, stage IC has poorer prognosis than IA1. However, adjuvant therapy did not improve survival, regardless of histologic subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsHumansFemaleNeoplasm StagingRetrospective StudiesChemotherapy, AdjuvantMiddle AgedAgedSEER ProgramChinaRadiotherapy, AdjuvantTreatment OutcomePrognosis

Stichwörter der Autor:innen

Cancer StagingChemotherapy, AdjuvantEndometrial CancerMolecular TypingRadiotherapy, AdjuvantSurvival

Autor:innen und Institutionen

  • Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and…
  • Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
  • Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China.

ORCID-Profile: Xiaolin Meng, Jing Yuan, Qian Zhang, Shuaiqingying Guo, Chaoyang Sun, Qing Zhang, Yingmei Wang, Kezhen Li, Jihui Ai, Jie Yang

Förderung

  • National Natural Science Foundation of China
  • National Key Technology Research and Development Program of China
  • National Clinical Research Centre of Obstetrics and Gynaecology

Zitieren

APA

Meng, X., Yuan, J., Zhang, Q., Guo, S., Sun, C., Zhang, Q., Wang, Y., Li, K., Ai, J., & Yang, J. (2026). Clinical outcomes and adjuvant therapy in stage IC endometrial cancer under the revised 2023 FIGO staging system: a multicenter analysis. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e57

Vancouver

Meng X, Yuan J, Zhang Q, Guo S, Sun C, Zhang Q, et al. Clinical outcomes and adjuvant therapy in stage IC endometrial cancer under the revised 2023 FIGO staging system: a multicenter analysis. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e57

BibTeX
@article{Meng2026,
  author = {Meng, Xiaolin and Yuan, Jing and Zhang, Qian and Guo, Shuaiqingying and Sun, Chaoyang and Zhang, Qing and Wang, Yingmei and Li, Kezhen and Ai, Jihui and Yang, Jie},
  title = {Clinical outcomes and adjuvant therapy in stage IC endometrial cancer under the revised 2023 FIGO staging system: a multicenter analysis},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e57}
}
Kostenlos starten →